Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639963 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1CFTRPOLBHTR4 | |
| SCHEMBL23698825 | 0.83 | CFTR (0.39) | KDM4EALDH1A1CFTRPOLBHTR4 | |
| SCHEMBL28947251 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1POLBHTR4ACHE | |
| SCHEMBL31115435 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1POLBHTR4ACHE | |
| SCHEMBL31417732 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1CFTRPOLBHTR4 | |
| SCHEMBL5042523 | 0.78 | HTR4 (0.54) | KDM4EALDH1A1HTR4ACHEHTR1A | |
| SCHEMBL24104578 | 0.77 | CFTR (0.39) | KDM4EALDH1A1CFTRPOLBHTR4 | |
| SCHEMBL30077253 | 0.74 | LMNA (0.42) | KDM4E | |
| SCHEMBL30077232 | 0.74 | LMNA (0.42) | KDM4E | |
| SCHEMBL10320877 | 0.72 | KDM4E (0.48) | KDM4EALDH1A1CFTRHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4501925-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-118715216-A | Nitrogen-containing heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | WEE1, WEE2, ERBB2 | KDM4E 4377/4885ALDH1A1 3477/4885CFTR 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.